Qiagen has acquired Parse Biosciences for an undisclosed amount. This corporate transaction sees Qiagen, a global provider of life science and diagnostic solutions, integrate Parse Biosciences’ innovative single-cell sequencing technology into its portfolio. The move marks a significant expansion for Qiagen in the rapidly growing field of single-cell analysis.
Parse Biosciences is a global life sciences company dedicated to accelerating progress in human health and scientific research. It empowers researchers to perform single-cell sequencing with unprecedented scale and ease through its pioneering Evercode technology, which enables instrument-free, high-throughput analysis. Parse’s solutions facilitate groundbreaking discoveries in areas such as cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system, complemented by its user-friendly Trailmaker data analysis software.
This acquisition is strategically aimed at enhancing Qiagen’s offerings in advanced genomic research tools. Parse Biosciences’ accessible, end-to-end solution, which includes various Evercode kits for whole transcriptome and immune profiling, removes the need for specialized instruments, making single-cell sequencing more broadly available to researchers. Its ability to process millions of cells and hundreds of samples in a single experiment without complex hardware aligns with Qiagen's commitment to delivering scalable and robust scientific solutions.
The integration of Parse Biosciences’ technology is expected to create significant synergies, allowing Qiagen to offer a more comprehensive suite of tools for advanced molecular analysis. By combining Parse’s innovative platform with Qiagen’s established market presence and extensive customer base, the combined entity is well-positioned to accelerate scientific discovery and broaden access to high-resolution single-cell insights across diverse research applications, ultimately contributing to advancements in human health.